Fat mass and obesity-associated protein (FTO) is the first reported RNA N6-
methyladenosine (m6A) demethylase in eukaryotic cells. m6A is considered as the most …

Angiogenesis is a vital process for the growth and dissemination of solid cancers. Numerous
molecular pathways are known to drive angiogenic switch in cancer cells promoting the …

Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the
mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its …

Ribosomal protein S6 (RPS6) is a component of the 40S small ribosomal subunit and
participates in the control of mRNA translation. Additionally, phospho (p)-RPS6 has been …

Simple Summary Several anti-angiogenic drugs have been approved for cancer treatment,
alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug …

Lung cancer is the leading cause of cancer mortality worldwide. Immunotherapy has
demonstrated clinically significant benefit for non-small-cell lung cancer, but innate (primary) …

The involvement of cardiovascular disease in cancer onset and development represents a
contemporary interest in basic science. It has been recognized, from the most recent …

Tumor endothelial cells (TECs) promote tumor angiogenesis and regulate cytotoxic T cells in
the tumor microenvironment. However, the roles of TECs for tumor‐infiltrating T‐cell in …

Multiple myeloma (MM) is still an incurable disease, despite considerable improvements in
treatment strategies, as resistance to most currently available agents is not uncommon. In …

Simple Summary Personalized cancer treatment strategies, including risk-adaptive
chemoradiation therapy based on medical imaging, seek to improve outcomes of patients …